Table 1.
Demographics and clinical measures for the DPS GWAS sample
| HC | SMC | EMCI | LMCI | AD | Total | |
|---|---|---|---|---|---|---|
| Sample size, n (%) | 226 (23.9) | 92 (9.7) | 267 (28.2) | 234 (24.7) | 125 (13.2) | 944 |
| Age at baseline PET, mean (SD) | 76.5 (6.5) | 72.6 (5.7) | 71.5 (7.2) | 74.7 (8.1) | 75.1 (7.9) | 74.1 (7.5) |
| Females, n (%) | 107 (47.3) | 55 (59.7) | 116 (43.4) | 95 (40.5) | 51 (40.8) | 424 (44.9) |
| Education, years, mean (SD) | 16.6 (2.7) | 16.8 (2.6) | 16.1 (2.7) | 16.3 (2.8) | 15.6 (2.7) | 16.3 (2.7) |
| APOE ɛ4+, n (%) | 60 (26.5) | 29 (31.5) | 118 (44.1) | 123 (52.5) | 83 (66.4) | 413 (43.7) |
| Amyloid+ at baseline PET | 85 (37.6) | 29 (31.5) | 133 (49.8) | 162 (69.2) | 110 (88.0) | 519 (54.9) |
| MMSE at baseline PET | 28.3 (2.5) | 28.8 (1.6) | 27.6 (2.7) | 23.4 (6.2) | 20.1 (4.8) | 25.9 (5.0) |
| Florbetapir SUVR at baseline PET | 0.74 (0.07) | 0.74 (0.07) | 0.77 (0.08) | 0.82 (0.09) | 0.87 (0.08) | 0.78 (0.09) |
| Hippocampal volume at baseline PET (normalized by intracranial volume) | 4.8 × 10−3 (6.9 × 10−4) | 5 × 10−3 (6 × 10−4) | 4.8 × 10−3 (7.3 × 10−4) | 4.1 × 10−3 (7.9 × 10−4) | 3.8 × 10−3 (6.2 × 10−4) | 4.5 × 10−3 (8.2 × 10−4) |
Values are mean ± standard deviation (SD), or n (% of the diagnostic group). Diagnosis at time of the first PET scan. The SUVR cut-off to determine amyloid status was obtained transforming the value of 0.79 recommended by Landau et al. (2015) by linear regression, yielding a value of 0.7585. AD = Alzheimer’s disease; EMCI = early MCI; HC = healthy control; LMCI = late MCI; SMC = subjective memory complaints.